Trial Profile

A Phase I, Single Arm, Dose Escalation Study to Evaluate Safety, Pharmacokinetics and Preliminary Efficacy of HL-085 Plus Vemurafenib in Patients With BRAF V600 Mutant Advanced Solid Tumor

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 15 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tunlametinib (Primary) ; Vemurafenib (Primary)
Indications Adenocarcinoma; Carcinoma; Non-small cell lung cancer; Pancreatic ductal carcinoma; Solid tumours; Thyroid cancer
Focus Adverse reactions
Sponsors Kechow Pharma

Most Recent Events

24 Oct 2023 Results (n=72; data cutoff date: 4 Nov 2022) presented at the 48th European Society for Medical Oncology Congress
29 May 2023 Planned End Date changed from 1 Aug 2022 to 1 Dec 2023.
29 May 2023 Planned primary completion date changed from 1 Aug 2022 to 1 Dec 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com